AU2020380968A1 - Treating liver disorders - Google Patents

Treating liver disorders Download PDF

Info

Publication number
AU2020380968A1
AU2020380968A1 AU2020380968A AU2020380968A AU2020380968A1 AU 2020380968 A1 AU2020380968 A1 AU 2020380968A1 AU 2020380968 A AU2020380968 A AU 2020380968A AU 2020380968 A AU2020380968 A AU 2020380968A AU 2020380968 A1 AU2020380968 A1 AU 2020380968A1
Authority
AU
Australia
Prior art keywords
compound
patient
liver
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020380968A
Other languages
English (en)
Inventor
Martijn Fenaux
Kevin Klucher
Yujin Wang
Weidong Zhong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terns Pharmaceuticals Inc
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of AU2020380968A1 publication Critical patent/AU2020380968A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020380968A 2019-11-08 2020-11-06 Treating liver disorders Abandoned AU2020380968A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962933277P 2019-11-08 2019-11-08
US62/933,277 2019-11-08
US202063004403P 2020-04-02 2020-04-02
US63/004,403 2020-04-02
PCT/US2020/059522 WO2021092474A1 (en) 2019-11-08 2020-11-06 Treating liver disorders

Publications (1)

Publication Number Publication Date
AU2020380968A1 true AU2020380968A1 (en) 2022-05-12

Family

ID=75849579

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020380968A Abandoned AU2020380968A1 (en) 2019-11-08 2020-11-06 Treating liver disorders

Country Status (11)

Country Link
EP (1) EP4054567A4 (enExample)
JP (1) JP2023501386A (enExample)
KR (1) KR20220098168A (enExample)
CN (1) CN114667142A (enExample)
AU (1) AU2020380968A1 (enExample)
BR (1) BR112022008639A2 (enExample)
CA (1) CA3160445A1 (enExample)
CL (1) CL2022001167A1 (enExample)
IL (1) IL292459A (enExample)
MX (1) MX2022005407A (enExample)
WO (1) WO2021092474A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4259279A1 (en) 2020-12-14 2023-10-18 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors
TW202539702A (zh) * 2024-03-08 2025-10-16 大陸商上海拓界生物醫藥科技有限公司 靶向ＩＮＨＢＥ的ＲＮＡｉ劑

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US20140187633A1 (en) * 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
MX2018011813A (es) * 2016-03-28 2019-01-24 Intercept Pharmaceuticals Inc Medicina obtenida mediante la combinacion de agonista fxr y arb.
WO2018170173A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
US20210121493A1 (en) * 2017-07-25 2021-04-29 Cedars-Sinai Medical Center Methods for treating liver diseases
EP3844156A4 (en) * 2018-08-30 2022-06-08 Terns Pharmaceuticals, Inc. TREATMENT OF LIVER DISEASES

Also Published As

Publication number Publication date
CN114667142A (zh) 2022-06-24
MX2022005407A (es) 2022-05-24
CL2022001167A1 (es) 2023-02-10
BR112022008639A2 (pt) 2022-07-19
WO2021092474A1 (en) 2021-05-14
IL292459A (en) 2022-06-01
CA3160445A1 (en) 2021-05-14
EP4054567A4 (en) 2024-01-10
KR20220098168A (ko) 2022-07-11
EP4054567A1 (en) 2022-09-14
JP2023501386A (ja) 2023-01-18

Similar Documents

Publication Publication Date Title
US20240316025A1 (en) Combination treatment of liver disorders
WO2021231644A1 (en) Combination treatment of liver disorders
US20190046471A1 (en) Methods and Compositions for the Treatment of Steatosis-Associated Disorders
Davis Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics
US20250099468A1 (en) Treating liver disorders with an ssao inhibitor
AU2017241559A1 (en) Medicine obtained by combining FXR agonist and ARB
CN119013027A (zh) 用于治疗肝脏病症的SSAO抑制剂和THR-β激动剂的组合
US20090093509A1 (en) Methods and Compositions for the Treatment of Pruritus
EP4054567A1 (en) Treating liver disorders
EP3743064B1 (en) Treatment of proteinuria
US20220387414A1 (en) Treating liver disorders
EP4223291A1 (en) Composition for treating kca3.1 channel-mediated diseases comprising phenylalkyl carbamate compound
HK40069155A (en) Treatment of proteinuria
Haddley Lu-AA-21004
Davis Liver disease and exogenous opioid pharmacokinetics
EP1846105A2 (en) Use of adrenergic alpha2b antagonists for the treatment of vasomotor symptoms

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application